

Ruth Dobson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3829050/publications.pdf>

Version: 2024-02-01

127
papers

5,379
citations

136950

32
h-index

91884

69
g-index

150
all docs

150
docs citations

150
times ranked

6691
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Practical Neurology, 2023, 23, 6-14.	1.1	13
2	Mental health of people with multiple sclerosis during the COVID-19 outbreak: A prospective cohort and cross-sectional case-control study of the UK MS Register. Multiple Sclerosis Journal, 2022, 28, 1060-1071.	3.0	18
3	Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 101-111.	1.9	16
4	<scp>COVID</scp>â€19 Vaccine Response in People with Multiple Sclerosis. Annals of Neurology, 2022, 91, 89-100.	5.3	119
5	Parkinson's Disease and Type 2 Diabetes: <scp>HbA1c</scp> Is Associated with Motor and Cognitive Severity. Movement Disorders, 2022, 37, 427-428.	3.9	6
6	CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103448.	2.0	19
7	Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary. Multiple Sclerosis Journal, 2022, 28, 326-327.	3.0	0
8	Social determinants of neurological disease: tackling inequalities. Lancet Neurology, The, 2022, 21, 122-123.	10.2	2
9	Dementia risk in a diverse population: A single-region nested case-control study in the East End of London. Lancet Regional Health - Europe, The, 2022, 15, 100321.	5.6	13
10	Seroconversion following COVID-19 vaccination: can we optimize protective response in CD20-treated individuals?. Clinical and Experimental Immunology, 2022, 207, 263-271.	2.6	14
11	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis Journal, 2022, 28, 1424-1456.	3.0	16
12	No evidence for association between polygenic risk of multiple sclerosis and MRI phenotypes in ~30,000 healthy adult UK Biobank participants. Multiple Sclerosis Journal, 2022, , 135245852210757.	3.0	2
13	Challenges and Opportunities of Real-World Data: Statistical Analysis Plan for the Optimise:MS Multicenter Prospective Cohort Pharmacovigilance Study. Frontiers in Neurology, 2022, 13, 799531.	2.4	0
14	Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population. JAMA Neurology, 2022, 79, 359.	9.0	25
15	Brain health: The hidden casualty of a humanitarian crisis. Lancet Regional Health - Europe, The, 2022, 15, 100374.	5.6	4
16	Lessons From the COVID-19 Pandemic to Improve the Health, Social Care, and Well-being of Minoritized Ethnic Groups With Chronic Conditions or Impairments: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2022, 11, e38361.	1.0	0
17	Age-specific effects of childhood body mass index on multiple sclerosis risk. Journal of Neurology, 2022, 269, 5052-5060.	3.6	5
18	Evaluating the feasibility of a real world pharmacovigilance study (OPTIMISE:MS). Multiple Sclerosis and Related Disorders, 2022, 63, 103894.	2.0	2

#	ARTICLE	IF	CITATIONS
19	Lower lymphocyte count is associated with increased risk of Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A94.3-A95.	1.9	0
20	Ethnic and socioeconomic determinants of dementia risk: a nested case-control study in East London. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A8.2-A8.	1.9	0
21	The impact of socioeconomic status and comorbidities on emergency admissions in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A138.3-A138.	1.9	0
22	Parkinson's disease determinants, prediction and gene-environment interactions: a UK Biobank study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, A7.3-A8.	1.9	0
23	Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 64, 103937.	2.0	18
24	Peripartum disease activity in moderately and severely disabled women with multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2022, 8, 205521732211049.	1.0	2
25	The shared genetic architecture of modifiable risk for Alzheimer's disease: a genomic structural equation modelling study. Neurobiology of Aging, 2022, 117, 222-235.	3.1	5
26	Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants. Multiple Sclerosis and Related Disorders, 2022, 64, 103963.	2.0	5
27	Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 65, 104022.	2.0	5
28	Digesting science: Developing educational activities about multiple sclerosis, prevention and treatment to increase the confidence of affected families. Multiple Sclerosis and Related Disorders, 2021, 47, 102624.	2.0	1
29	Estimated and projected burden of multiple sclerosis attributable to smoking and childhood and adolescent high body-mass index: a comparative risk assessment. International Journal of Epidemiology, 2021, 49, 2051-2057.	1.9	9
30	Self-diagnosed COVID-19 in people with multiple sclerosis: a community-based cohort of the UK MS Register. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 107-109.	1.9	38
31	Lower Lymphocyte Count is Associated With Increased Risk of Parkinson's Disease. Annals of Neurology, 2021, 89, 803-812.	5.3	38
32	Treatment of Women with Multiple Sclerosis Planning Pregnancy. Current Treatment Options in Neurology, 2021, 23, 11.	1.8	43
33	Use of disease-modifying drugs during pregnancy and breastfeeding. Current Opinion in Neurology, 2021, 34, 303-311.	3.6	18
34	Perinatal Depression and Anxiety in Multiple Sclerosis. Neurology, 2021, 96, 1067-1068.	1.1	1
35	Demyelinating Events Following Initiation of Anti-TNF α Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurology: Neuroimmunology and Neuroinflammation, 2021, 8, .	6.0	16
36	Current review and next steps for artificial intelligence in multiple sclerosis risk research. Computers in Biology and Medicine, 2021, 132, 104337.	7.0	10

#	ARTICLE	IF	CITATIONS
37	Gene-Environment Interactions in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	32
38	The Influence of Socioeconomic Deprivation on Dementia Mortality, Age at Death, and Quality of Diagnosis: A Nationwide Death Records Study in England and Wales 2001â€“2017. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 321-328.	2.6	19
39	Differing Impact of Disease-Modifying Therapy on Relapse and Progression. <i>Neurology</i> , 2021, 97, 407-408.	1.1	0
40	Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 103028.	2.0	20
41	COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 52, 102939.	2.0	34
42	UK variance in DMT advice and prescribing in MS and pregnancy: Impact of the UK consensus on pregnancy in multiple sclerosis ABN guidelines. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 56, 103272.	2.0	4
43	Evaluation of remote assessments for multiple sclerosis in an in-home setting. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 54, 103125.	2.0	2
44	W26. A MULTIVARIATE GENOME-WIDE ASSOCIATION STUDY OF MODIFIABLE RISK FOR ALZHEIMER'S DISEASE: 269 LOCI ASSOCIATED WITH BRAIN HEALTH. <i>European Neuropsychopharmacology</i> , 2021, 51, e159.	0.7	0
45	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. <i>BMJ Open</i> , 2021, 11, e050176.	1.9	3
46	Predicting Multiple Sclerosis: Challenges and Opportunities. <i>Frontiers in Neurology</i> , 2021, 12, 761973.	2.4	7
47	The Multiple Sclerosis Data Alliance Catalogue. <i>International Journal of MS Care</i> , 2021, 23, 261-268.	1.0	3
48	Big data, machine learning and artificial intelligence: a neurologistâ€™s guide. <i>Practical Neurology</i> , 2020, , practneurol-2020-002688.	1.1	14
49	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	3.0	50
50	Sex effects across the lifespan in women with multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642093616.	3.5	58
51	MS, pregnancy and COVID-19. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1137-1146.	3.0	10
52	Summary-data-based Mendelian randomization prioritizes potential druggable targets for multiple sclerosis. <i>Brain Communications</i> , 2020, 2, fcaa119.	3.3	16
53	Parkinsonâ€™s disease determinants, prediction and geneâ€™environment interactions in the UK Biobank. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 1046-1054.	1.9	59
54	Regarding: Nicotinic acetylcholine receptors Î±7 and Î±9 modify tobacco smoke risk for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 27, 135245852096994.	3.0	0

#	ARTICLE	IF	CITATIONS
55	Prevalence and demographics of multiple sclerosis-associated uveitis: a UK biobank study. Multiple Sclerosis and Related Disorders, 2020, 43, 102209.	2.0	4
56	Change in pregnancy-associated multiple sclerosis relapse rates over time: a meta-analysis. Multiple Sclerosis and Related Disorders, 2020, 44, 102241.	2.0	21
57	Epidemiology of Epstein-Barr virus infection and infectious mononucleosis in the United Kingdom. BMC Public Health, 2020, 20, 912.	2.9	90
58	Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors. Multiple Sclerosis Journal, 2020, 26, 1281-1297.	3.0	55
59	Protecting people with multiple sclerosis through vaccination. Practical Neurology, 2020, 20, 435.1-445.	1.1	40
60	Family planning is the second most relevant factor for treatment decisions after disease activity - Commentary. Multiple Sclerosis Journal, 2020, 26, 644-644.	3.0	0
61	BMI and low vitamin D are causal factors for multiple sclerosis. Neurology: Neuroimmunology and Neuroinflammation, 2020, 7, .	6.0	67
62	Ethnic and Socioeconomic Associations with Multiple Sclerosis Risk. Annals of Neurology, 2020, 87, 599-608.	5.3	21
63	Breastfeeding may reduce postpartum relapse in some women with multiple sclerosis. Neurology, 2020, 94, 769-770.	1.1	2
64	Remote testing of vitamin D levels across the UK MS population - A case control study. PLoS ONE, 2020, 15, e0241459.	2.5	2
65	Pregnancy in multiple sclerosis: influence on disease trajectory. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 2020, 19, 15-16.	0.1	0
66	Remote testing of vitamin D levels across the UK MS population - A case control study. , 2020, 15, e0241459.		0
67	Remote testing of vitamin D levels across the UK MS population - A case control study. , 2020, 15, e0241459.		0
68	Remote testing of vitamin D levels across the UK MS population - A case control study. , 2020, 15, e0241459.		0
69	Remote testing of vitamin D levels across the UK MS population - A case control study. , 2020, 15, e0241459.		0
70	Visibility and representation of women in multiple sclerosis research. Neurology, 2019, 92, 713-719.	1.1	13
71	UK consensus on pregnancy in multiple sclerosis: - Association of British Neurologists - guidelines. Practical Neurology, 2019, 19, 106-114.	1.1	118
72	Clinical commentary on - Life-threatening vitamin D intoxication due to intake of ultra-high doses in multiple sclerosis: a note of caution - . Multiple Sclerosis Journal, 2019, 25, 1328-1329.	3.0	0

#	ARTICLE	IF	CITATIONS
73	Multiple sclerosis – a review. European Journal of Neurology, 2019, 26, 27-40.	3.3	1,057
74	Vitamin D supplementation. Practical Neurology, 2018, 18, 35-42.	1.1	43
75	Epstein-Barr –negative MS: a true phenomenon?. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e318.	6.0	33
76	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, jnnp-2014-309690.	1.9	90
77	A Risk Score for Predicting Multiple Sclerosis. PLoS ONE, 2016, 11, e0164992.	2.5	11
78	The difficulties with vitamin B ₁₂ . Practical Neurology, 2016, 16, 308-311.	1.1	12
79	Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease. Current Osteoporosis Reports, 2016, 14, 199-210.	3.6	13
80	The effects of intrathecal rituximab on biomarkers in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2016, 6, 49-53.	2.0	47
81	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. Multiple Sclerosis Journal, 2016, 22, 1349-1358.	3.0	54
82	Atraumatic needles for lumbar puncture: why haven't neurologists changed?. Practical Neurology, 2016, 16, 18-22.	1.1	17
83	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Multiple Sclerosis Journal, 2015, 21, 1013-1024.	3.0	249
84	Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 273-279.	1.9	144
85	The Refinement of Genetic Predictors of Multiple Sclerosis. PLoS ONE, 2014, 9, e96578.	2.5	15
86	Assessing treatment response to interferon- β . Neurology, 2014, 82, 248-254.	1.1	61
87	Bone health in Parkinson's disease: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1159-1166.	1.9	114
88	Change practice now! Using atraumatic needles to prevent post lumbar puncture headache. European Journal of Neurology, 2014, 21, 305-311.	3.3	32
89	Multiple sclerosis therapy and Epstein-Barr virus antibody titres. Multiple Sclerosis and Related Disorders, 2014, 3, 372-374.	2.0	15
90	Sustained-release fampridine in Multiple Sclerosis. Multiple Sclerosis and Related Disorders, 2014, 3, 17-21.	2.0	2

#	ARTICLE	IF	CITATIONS
91	A service development study of the assessment and management of fracture risk in Parkinson's disease. Journal of Neurology, 2014, 261, 1153-1159.	3.6	19
92	Validating a novel web-based method to capture disease progression outcomes in multiple sclerosis. Journal of Neurology, 2013, 260, 2505-2510.	3.6	35
93	Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis. Journal of Neurology, 2013, 260, 1272-1285.	3.6	57
94	Bone health in chronic neurological diseases: a focus on multiple sclerosis and parkinsonian syndromes. Practical Neurology, 2013, 13, 70-79.	1.1	24
95	The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 162-166.	3.0	139
96	The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis. Multiple Sclerosis Journal, 2013, 19, 1571-1579.	3.0	84
97	The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 427-432.	1.9	132
98	Genome-wide association studies: will we ever predict susceptibility to multiple sclerosis through genetics?. Expert Review of Neurotherapeutics, 2013, 13, 235-237.	2.8	4
99	Comparison of two commercial ELISA systems for evaluating anti-EBNA1 IgG titers. Journal of Medical Virology, 2013, 85, 128-131.	5.0	7
100	Cerebrospinal fluid and urinary biomarkers in multiple sclerosis. Acta Neurologica Scandinavica, 2013, 128, n/a-n/a.	2.1	17
101	Assessing fracture risk in people with MS: a service development study comparing three fracture risk scoring systems. BMJ Open, 2013, 3, e002508.	1.9	10
102	THINK OUTSIDE THE BOX, COLLAPSE THE BOX, AND TAKE A SHARP KNIFE TO IT!. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, e2.83-e2.	1.9	0
103	Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone. ISRN Neurology, 2013, 2013, 1-8.	1.5	8
104	Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 909-914.	1.9	293
105	Bone health in multiple sclerosis: should we be doing more?. Neurodegenerative Disease Management, 2013, 3, 401-403.	2.2	0
106	Increased Neurofilament Light Chain Blood Levels in Neurodegenerative Neurological Diseases. PLoS ONE, 2013, 8, e75091.	2.5	375
107	158€...Why can't I win any more?. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.114-e1.	1.9	0
108	Risk of fractures in patients with multiple sclerosis: A population-based cohort study. Neurology, 2012, 79, 1934-1935.	1.1	4

#	ARTICLE	IF	CITATIONS
109	Bone health and multiple sclerosis. Multiple Sclerosis Journal, 2012, 18, 1522-1528.	3.0	40
110	148â€¦The effect of natalizumab and interferon-Î² on urinary free light chains and anti-EBV nuclear antigen-1 antibodies in relapsing remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, e1.102-e1.	1.9	0
111	CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON Î²: A SYSTEMATIC REVIEW AND META-ANALYSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, A34.3-A34.	1.9	0
112	The effect of gender in clinically isolated syndrome (CIS): a meta-analysis. Multiple Sclerosis Journal, 2012, 18, 600-604.	3.0	37
113	Blood glucose monitoring using microwave cavity perturbation. Electronics Letters, 2012, 48, 905.	1.0	19
114	Genomic Regions Associated with Multiple Sclerosis Are Active in B Cells. PLoS ONE, 2012, 7, e32281.	2.5	16
115	Meta-Analysis of the Relationship between Multiple Sclerosis and Migraine. PLoS ONE, 2012, 7, e45295.	2.5	49
116	Urine: An under-studied source of biomarkers in multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2012, 1, 76-80.	2.0	7
117	Melanoma associated retinopathy and how to understand the electroretinogram. Practical Neurology, 2011, 11, 234-239.	1.1	13
118	Viral pathophysiology of multiple sclerosis: A role for Epstein-Barr virus infection?. Pathophysiology, 2011, 18, 13-20.	2.2	19
119	Smoking and Multiple Sclerosis: An Updated Meta-Analysis. PLoS ONE, 2011, 6, e16149.	2.5	220
120	More to come: Humoral immune responses in MS. Journal of Neuroimmunology, 2011, 240-241, 13-21.	2.3	7
121	Vitamin D deficiencyâ€“do we follow our own advice?. Clinical Medicine, 2011, 11, 521-523.	1.9	0
122	Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurology, The, 2010, 9, 727-739.	10.2	459
123	Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. Journal of Neuroimmunology, 2010, 220, 99-103.	2.3	8
124	POI18 Increased urinary free immunoglobulin light chain excretion in patients with multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e57-e57.	1.9	2
125	A response to Cappuccio F et al.: 'Implementing a 48 h EWTD-compliant rota for junior doctors in the UK does not compromise patients' safety: assessor blind pilot comparison.'. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 297-298.	0.5	4
126	Achieving high standards of training. Clinical Medicine, 2009, 9, 514-514.	1.9	1

#	ARTICLE	IF	CITATIONS
127	Ethnicity and multiple sclerosis - moving beyond preconceptions. Advances in Clinical Neuroscience & Rehabilitation: ACNR, 0, 20, .	0.1	2